F.D.A. Moves to Speed Approvals for Cheaper Copycat Drugs
PositiveScience

The F.D.A. is taking significant steps to expedite the approval process for biosimilar drugs, which are essentially cheaper alternatives to brand-name medications. This move is crucial as it aims to reduce drug costs for consumers, making essential treatments more accessible. One notable example is Amjevita, a biosimilar version of the popular arthritis drug Humira, which has been part of a growing market of similar products over the last decade. By cutting regulatory hurdles, the F.D.A. is not only fostering competition but also encouraging innovation in the pharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System






